Please use this identifier to cite or link to this item: https://hdl.handle.net/10137/8003
Email LibraryRMU.DOH@nt.gov.au to ask for this document in a different format
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMorigi, Joshua James
dc.contributor.authorAnderson, Jack
dc.contributor.authorFanti, Stefano
dc.date.accessioned2020-01-07T03:32:26Z-
dc.date.available2020-01-07T03:32:26Z-
dc.date.issued2020-01
dc.identifier.citationCurrent opinion in urology 2020-01; 30(1): 9-16
dc.identifier.urihttps://hdl.handle.net/10137/8003-
dc.description.abstractProstate cancer is a high prevalence malignancy whose management is a major challenge for clinicians worldwide. Molecular imaging, and in particular PET with computed tomography (PET/CT), is increasingly gaining importance in the work up and management of all prostate cancer patients. PET/CT remains, however, an expensive imaging modality and currently not reimbursed. Although other PET tracers are available and have gained institutional recognition from regulatory agencies, prostate-specific membrane agents (PSMA)-based PET/CT tracers have demonstrated the highest sensitivity and specificity for prostate cancer, outperforming any other PET radioligand to date. Regardless of the clinical scenario (staging, biochemical recurrence, therapy response assessment in advanced prostate cancer) PSMA PET/CT scans have become common practice in countries allowing for use outside of controlled clinical trials because of the overwhelming evidence demonstrating the extremely high sensitivity of this imaging modality in identifying prostate cancer lesions. This evidence can make PSMA PET/CT appealing for clinicians and lead to unnecessary scanning with limited supporting evidence. Our aim is to provide an update on the most recent literature available on PET-based imaging for prostate cancer and particularly PSMA PET/CT, offering an expert opinion on the data collected to provide clinicians with guidance on appropriateness and efficacy of PET-based imaging, in order to maximize clinical benefits and avoid waste of resources.
dc.description.provenanceMade available in DSpace on 2020-01-07T03:32:26Z (GMT). No. of bitstreams: 0 Previous issue date: 2020-01en
dc.language.isoeng
dc.titlePromise of PET imaging in prostate cancer: improvement or waste of money?
dc.typeJournal Article
dc.identifier.journaltitleCurrent opinion in urology
dc.identifier.doi10.1097/MOU.0000000000000684
dc.identifier.pubmedidhttps://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/31652164
dc.identifier.affiliationPET/CT Unit, Royal Darwin Hospital, Darwin, Northern Territory, Australia..
dc.identifier.affiliationPET/CT Unit, Royal Darwin Hospital, Darwin, Northern Territory, Australia..
dc.identifier.affiliationMetropolitan Nuclear Medicine Service, S.Orsola-Malpighi Hospital, University of Bologna, Italy..
dc.identifier.pubmedurihttps://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/31652164
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.


Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.